NCT04550494 2026-03-19
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
Fondazione per la Medicina Personalizzata
Oslo University Hospital